The study data demonstrated that the system is safe and feasible during elective percutaneous coronary intervention (PCI) using a femoral vein approach.

Miracor CEO Jon Hoem said they are extremely pleased to have successfully completed the ‘Prepare PICSO’ study and now look forward with to the ‘Prepare RAMSES’ study.

"The ‘Prepare RAMSES’ study will help us understand the logistics of the technology in an acute setting and also how the technology effects important endpoints such as infarct size, ST-segment ECG changes, enzyme release and left ventricular function," Hoem said.